Waldenstrom Macroglobulinemia Clinical Trials

A listing of Waldenstrom Macroglobulinemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenstr m's Macroglobulinaemia

This study is for patients who have previously been treated for Waldenstrm's macroglobulinaemia (WM) and their disease has either not responded (known as refractory disease) or has returned

bone marrow procedure
igm level
measurable disease
rituximab
  • 3 views
  • 27 May, 2021
  • 12 locations
Efficacy of First Line B-RI for Treatment Naive Waldenstr m's Macroglobulinemia

In Waldenstrm macroglobulinemia (WM) conventional chemotherapy induces only low complete remission (CR) rates and responses of short duration compared to other indolent lymphomas. Thus

cancer
cold agglutinin
rituximab
chemotherapy regimen
neutrophil count
  • 11 views
  • 25 Jan, 2021
  • 28 locations
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific

cancer
igm level
ibrutinib
measurable disease
bone marrow procedure
  • 0 views
  • 27 Jan, 2021
  • 1 location
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrm macroglobulinemia

neutrophil count
chronic lymphocytic leukemia
blood transfusion
b-cell lymphoma
leukemia
  • 16 views
  • 28 Apr, 2021
  • 30 locations
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

This phase II trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a period of improvement (relapsed) or have not responded to treatment (refractory). Immunotherapy with monoclonal antibodies, such as …

pembrolizumab
cancer
gilbert's syndrome
chemotherapy regimen
neutrophil count
  • 45 views
  • 07 Mar, 2021
  • 2 locations
Chemotherapy Total Body Irradiation and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

This phase II trial studies how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant. Drugs used in the chemotherapy, such as fludarabine phosphate and melphalan hydrochloride, work in different ways …

cancer
myeloproliferative neoplasm
total body irradiation
sirolimus
chemotherapy regimen
  • 45 views
  • 27 Jan, 2021
  • 1 location
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Lymphocytic Leukemia (CLL) and waldenstrom Macroglobulinemia (WM).It is under constant investigation for the treatment of other B-cell malignancies. The initial approval of ibrutinib was received on 13

cancer
gilbert's syndrome
rituximab
neutrophil count
chronic lymphocytic leukemia
  • 0 views
  • 22 Jan, 2021
  • 2 locations
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

This is a single arm, phase II trial of HLA-haploidentical related hematopoietic cells transplant (Haplo-HCT) using reduced intensity conditioning (fludarabine and melphalan and total body irradiation). Peripheral blood is the donor graft source. This study is designed to estimate disease-free survival (DFS) at 18 months post-transplant.

cancer
blast cells
myeloproliferative neoplasm
total body irradiation
chemotherapy regimen
  • 5 views
  • 11 Mar, 2021
  • 1 location
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.

plasma cell leukemia
cancer
gilbert's syndrome
myeloproliferative neoplasm
minimal residual disease
  • 42 views
  • 25 Jan, 2021
  • 1 location
Allo HSCT Using RIC for Hematological Diseases

This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD with an updated GVHD prophylaxis of tacrolimus …

tacrolimus
plasma cell leukemia
cancer
blast cells
total body irradiation
  • 27 views
  • 31 May, 2021
  • 1 location